The overwhelming female predominance in Alzheimer disease—affecting nearly two-thirds of patients—may stem from biological vulnerabilities during menopause rather than simply women living longer than men. This reframing transforms midlife from a passive aging phase into an active intervention opportunity that could reshape dementia prevention strategies globally.
Specific neuroendocrine changes during perimenopause and menopause appear to accelerate Alzheimer pathology through hormonal disruptions. Early menopause, surgical removal of ovaries before natural menopause, severe hot flashes, and midlife cognitive fog all correlate with elevated dementia risk decades later. These factors suggest estrogen's neuroprotective effects extend far beyond reproductive function, influencing brain metabolism, inflammation, and amyloid clearance mechanisms that deteriorate as hormone levels decline.
This hormonal hypothesis opens previously unexplored therapeutic avenues. Current evidence hints that properly timed hormone replacement therapy might preserve cognitive function, particularly for women who undergo surgical menopause. However, the field lacks the rigorous clinical trials and biomarker studies needed to validate optimal timing, formulations, and patient selection criteria.
The implications extend beyond individual treatment decisions. With over 1.2 billion women approaching menopause by 2050, identifying midlife as a prevention window could fundamentally alter public health approaches to dementia. Rather than waiting for cognitive symptoms in later life, interventions targeting neuroendocrine aging during the fifth and sixth decades might prove more effective than current strategies. This shift from reactive to proactive care represents a potential paradigm change in how medicine approaches neurodegenerative disease prevention through sex-specific, biologically-informed interventions.
